Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01

by Lynch RM, Tran L, Wu X, Li Y, Lee B, Mascola J
Published 2012-09-01

454 pyrosequencing and bioinformatics analysis of the lineage of the broad and potent gp41-directed antibody 10e8

by Ofek G, Zhu J, Yang Y, Zhang B, Mckee K, Louder M, Huang J, Laub L, Connors M, Mascola J, Kwong PD
Published 2012-09-01

P04-41. Kinetics of antibody neutralization and viral evolution following envelope vaccination in SIV-infected rhesus monkeys

by Korber B, Nabel G, Mascola J, Rao S, Giri A, Hraber P, Whitney J, Coffey R, Yeh W, Basavapathruni A, Seaman M, Letvin N
Published 2009-10-01

Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial

by Williams WB, Jones K, Krambrink A, Grove D, Liu P, Yates NL, Moody MA, Ferrari G, Pollara J, Moodie Z, Morgan CA, Liao H, Montefiori DC, Ochsenbauer C, Kappes J, Hammer S, Mascola J, Koup R, Corey L, Nabel G, Gilbert P, Churchyard G, Keefer M, Graham BS, Haynes BF, Tomaras GD
Published 2012-09-01